Proteflazid® effectiveness for prevention and treatment of acute viral respiratory infections in the conditions of COVID-19.

The original antiviral drug Proteflazid® has been used in clinical practice since the early 2000s for the etiotropic treatment of acute respiratory viral diseases, due to its property of blocking viral RNA and DNA polymerases. Considering that at the beginning of the global COVID- 19 pandemic, caused by RNA-containing virus of SARS-CoV-2 species in 2020, the ability of the drug active substance to inhibit the activity of 3CL- protease of the SARS-CoV-2 coronavirus was shown by molecular docking and, subsequently, to confirm the property of the active substance to block the reproduction of the SARS-CoV-2 virus in cell cultures in vitro. It was extremely important to test the effectiveness of the drug Proteflazid, drops for the prevention and treatment of COVID-19 disease at "off labell use". AIM: The aim of the study was to provide a statistical assessment of the effectiveness of the drug Proteflazid®, drops in terms of COVID-19 pandemic. MATERIALS AND METHODS: The analysis has been performed including the letters-references from medical institutions from different regions of Ukraine about the effectiveness of the drug Proteflazid®, drops. Methods of statistical analysis have been focused on dynamics and structure analysis, meta-analysis, generalization, etc. RESULTS: 90 letters-references about the effectiveness of the drug Proteflazid®, drops, during the prevention and treatment of acute respiratory viral infections, including COVID-19 diseases were analyzed. The study used references that contained the most complete information. The number of deleted letters-references is 11. Lettersreferences from 79 medical institutions from different cities and regions of Ukraine were analyzed. The period of starting taking the drug by employees and patients of medical institutions began on February 27, 2020. Final information - October 01, 2020. The vast majority of letters from medical institutions indicated that medical staff were in contact with patients potentially suffering from COVID-19. This means a high risk of being infected with Coronavirus infection. Total number of patients who took Proteflazid® for preventive purpose was 8,572, including 7,444 medical workers and 1,128 ordinary patients. Indicator "Number of fatalities" for the medical institutions providing such information was "0". Total number of patients who took Proteflazid® for therapeutic purposes was 433, including 23 medical workers and 410 ordinary patients. Indicator "Number of fatalities" for the medical institutions providing such information was "0". The total number of medical personnel and patients who used Proteflazid drops for preventive and therapeutic purposes was 9005 people. CONCLUSIONS: The statistical analysis confirmed the effectiveness of the drug Proteflazid® for the prevention and treatment of COVID-19, as, when compared with official actual data, regarding the main indicators of the incidence of COVID-19: there were no fatalities; the average treatment period decreased (1.8 times); the proportion of recovered increased (at least 1.5 times); the proportion of sick medical workers in the total population of sick medical workers decreased (2.2 times); the proportion of patients with a severe course decreased (3.3 times). It can be argued that the drug Proteflazid®, drops has shown high effectiveness in the prevention and treatment of acute respiratory viral infections, including COVID-19, among medical personnel and patients.

Analysis of the clinical trial results of the flavonoid effects on some cellular immunity indicators in children and adults.

In the scope of this paper, an analysis of the clinical trial results assessing the clinical and immunological efficacy of the effects of flavonoids on some indicators of immunity in children and adults is given. AIM: The aim of the study was to evaluate the effects of flavonoids on the cellular component of the immune system in children and adults with viral and viral-bacterial diseases by using meta-analysis and statistical analysis of the clinical findings. MATERIALS AND METHODS: The analysis comprises 5 scientific sources with the results of controlled clinical trials involving 412 children and 15 sources involving 1493 adult patients during the period from 2003 to 2017. In analysis Student's t-test was applied. RESULTS: The data obtained indicate the efficacy of flavonoids in the treatment of viral and viral-bacterial diseases in children and adults. The administration of flavonoids (Proteflazid®, Immunoflazid®, Flavozid®) in the treatment of children with acute respiratory diseases and adults with HHV infection contributes to the normalization of cellular immunity indicators, the HHV infections symptom resolution, and the relapse rate reduction of genital herpes caused by HHV infection. CONCLUSIONS: Therapy with such medical products as Proteflazid®, Immunoflazid®, Flavozid® helps to improve the clinical status and normalize the cellular immunity indicators in patients who were administered a treatment course.

Proteflazid®: outcome analysis of clinical trials studying the impact of human herpesvirus infection on some cellular immunity indicators and gestation course in women.

An outcome analysis of the clinical trials evaluating the clinical and immunological efficacy of the drug Proteflazid® in the treatment of diseases associated with herpesvirus infection in pregnant women is presented. AIM: Objective of the study was to evaluate the effects of Proteflazid® on the cellular component of the immune system and gestation course in women with HHV infection by using meta-analysis and statistical analysis (based on Student's t-test) of the clinical findings. MATERIALS AND METHODS: The analysis comprises 5 scientific sources with the results of controlled clinical trials involving 234 pregnant women during the period from 2003 to 2012. RESULTS: The obtained data prove the efficacy of the preparation Proteflazid ® in treating pregnant women with HHV infection. Administration of the drug Proteflazid® in the treatment of herpesvirus infection in pregnant women contributes to the cellular immunity normalization, which in turn has a positive effect on the course and outcome of pregnancy. CONCLUSIONS: Therapy with the drug Proteflazid® is etiologically and pathogenetically substantiated, contributes to the normalization of cellular immunity parameters, which, in turn, has a positive effect on the course and outcome of pregnancy.

PROTEFLAZID®: clinical studies as evidence base of its antiviral activity.

The article contains the results of many years of clinical studies of efficiency and safety of the preparation Proteflazid®, obtained from the wild cereals Deschampsia caespitosa L. and Calamagrotis epigeios L. Proteflazid® has direct antiviral and anti-relapsing effects in various disease of viral etiology, registered in more than 230 clinical studies.

Proteflazid®: treatment of herpesvirus and mixed infections. Meta-analysis of clinical trials results.

There is a meta-analysis of clinical trials results concerning the evaluation of efficiency of the drug Proteflazid® (drops) in the treatment of adult patients with herpesvirus and mixed infections. AIM: Objective of the study: to evaluate the clinical efficacy of the drug Proteflazid® in a treatment of herpesvirus (HSV-1, HSV-2) and mixed infections in adults by meta-analysis of clinical trials. MATERIALS AND METHODS: In meta-analysis, 16 scientific sources with results of controlled studies with participation of 1336 patients over 18 y.o. during 2003-2015 are included. RESULTS: Obtained data are indicative of efficiency of the drug Proteflazid® in the treatment of patients with herpesvirus and mixed infections. Proteflazid® induces improvement in the main clinical signs of diseases, promotes elimination of herpesviruses from organism and prevention of relapses. CONCLUSIONS: Proteflazid® in the therapy of various clinical forms of HHVs infection promotes the improvement in the main clinical signs of diseases, elimination of HSV-1 and HSV-2; prevention of relapses of diseases (ophthalmoherpes, genital herpes) after completion of the treatment. Therapy of mixed infections (HSV, bacteria, protozoa, fungi) using the drug Proteflazid® promotes improvement in the main clinical signs of diseases, improvement in vaginal mircoflora condition and improvement in local changes in the cervix in women with inflammatory diseases of genital organs as well as in prevention of relapses of genital inflammatory diseases and chronic pyelonephritis.

Proteflazid®: Clinical experience in children of young and preschool age - systematic review of postmarketing surveillance.

Scientific literature data on the experience of use of Proteflazid® (drops) and Immunoflazid® (syrup) for the treatment of viral diseases in children of the first six years of life are analysed in the article. A systematic review was conducted on the basis of postmarketing comparative clinical trials and long-term follow-up (during the period of 2002 to 2016) that involved about 1500 children (the intent-to-treat population comprised more than 800 of them). The safety and efficacy of the Proteflazid® (drops) and Immunoflazid® (syrup) usage in children for the treatment of viral infections have been proven.

Proteflazid® and local immunity in diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections.

Reporting of clinical trials results for Proteflazid® in the drug formulation suppositories and vaginal swabs soaked in the solution of the drug to the local immunity of the female reproductive tract. AIM: The aim of study was to examine the state of local immunity in the reproductive tract of women with sexually transmitted diseases caused by human papillomavirus, herpes viruses (Type 1, 2) and mixed infection (herpes viruses + chlamydia). MATERIALS AND METHODS: The trials involved 216 women with viral sexually transmitted diseases: Cervical Dysplasia associated with papillomavirus infection (HPV) (Group 1); Herpes genitalis type 1 (HSV- 1) and type 2 (HSV-1) (Group 2); mixed infection - HSV-1, HSV-2 and chlamydia (Group 3). RESULTS: Treatment results have confirmed that Proteflazid® contributes to sustainable performance improvement of basic factors of local immunity - sIgA, lysozyme and complement component C3 in the cervical mucus for all three groups of women. CONCLUSIONS: Proteflazid® enhances level of local immunity markers (sIgA, lysozyme, C3 complement component) and improves their ratios. Also it intensifies anticontagious activity of mucosal protection and female reproductive system as whole, during treatment diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections (herpesvirus and chlamydia).